Amryt Pharma Share Discussion Threads

[alphabravo321] 21/1/2021 09:08

Yep I have tried that a few times, it would be easier to get in touch with Biden!

[bazworth] 21/1/2021 09:06

I would suggest you contact IG directly. I use iii and all three of the rights are clearly shown Good luck!

[alphabravo321] 21/1/2021 08:30

Anyone figure out how to get CVRS showing on an IG account?

[papillon] 20/1/2021 23:09

free stock charts from uk.advfn.com

[papillon] 20/1/2021 23:08

The chart trend of AMYT is most definitely upwards https://uk.advfn.com/p.php?pid=chartscreenshot&u=YRQWBska4OZTAl4SADqiUYMDaQtHhdXe

[papillon] 20/1/2021 22:40

"I expect the first cash to come in this year." That would be very nice, sidam. I hope you are correct!

[sidam] 20/1/2021 22:33

My CVRs are still shown as a holding in my ISA. I am certainly not going to rock the boat by asking if that is OK. I expect the first cash to come in this year.

[moorsie2] 20/1/2021 19:27

Stock has been hard to get. Would expect significant rises in the coming days

[alphabravo321] 20/1/2021 17:56

More big trades coming through

[waterloo01] 20/1/2021 16:38

Might be right. I hold in a SIPP but the rules are different to ISA's

[bermudashorts] 20/1/2021 16:26

Yep that's my understanding too but don't think CVRs can be held in an ISA.

[richman777114] 20/1/2021 16:08

thanksIR didn't reply to my email and couldn't find anything on web

[waterloo01] 20/1/2021 15:53

richman, yes my understanding as well unless held in a tax wrapper (ISA etc).

[delta0091] 20/1/2021 15:46

Currently, only 11.3 mg vials (10 mg dose) metreleptin are available at a list price of £2,335 per vial. The availability of smaller vial sizes is expected within three months of submission of the variation to marketing authorisation, at a list price of £1,167.50 for a 5.8 mg vial (5 mg dose) and £583.80 for a 3 mg vial (2.5 mg dose). Based on the distribution (11.54% 10 mg dose; 69.23% 5 mg dose; 19.23% 2.5 mg dose) of observed current doses in the UK early access programme (EAP), an average annual per patient price of £434,633 is assumed in the analysis. Due to a loss of drug exclusivity after 10 years, a decrease of 90% of the list price of metreleptin was assumed in the model in one of the scenario analyses. hxxps://www.nice.org.uk/guidance/gid-hst10011/documents/evaluation-consultation-document hxxps://www.engage.england.nhs.uk/consultation/metreleptin-for-congenital-leptin-deficiency/user_uploads/metreleptin-impact-assessment.pdf ==== there's around 70 people in the uk suffering from this illness potential yearly revenue : over £50m

[richman777114] 20/1/2021 15:34

hello,does anyone know the tax treatment re the CVRs?my assumption is that the issue of them was not a taxable event vis a vis shareholders and that any cash received following the achievement of milestones is subject to cgt with a nil base cost

[delta0091] 20/1/2021 15:25

Andra Stratton @livinlavidalopo · 1h OMG! This is THE BEST NEWS!!! I am in tears of joy for my #lipodystrophy family in UK. @LDUK was relentless in their efforts to unite stakeholders and get this result. Patients for the win again! Bravo @Becky_Sanders_ #PatientAdvocacy

[delta0091] 20/1/2021 15:24

the sheer joy of this lady, regarding today's news, is inspiring https://twitter.com/i/status/1351830442115280897

[babbler] 20/1/2021 14:19

USA will help this share. UK investors need a kick.

[alphabravo321] 20/1/2021 14:01

Strange the number of shares bought at 1235 is exactly 5 times the first trade on Nasdaq of 69054

[waterloo01] 20/1/2021 13:20

the best kind!

[cwa1] 20/1/2021 13:19

Delayed gratification...

[moorsie2] 20/1/2021 12:54

wow - the lack of movement here this morning has been curious alright

[alphabravo321] 20/1/2021 12:51

Advfn is showing a buy at 200p at 1235 for 345,270 shares

[moorsie2] 20/1/2021 12:49

How much? I cannot see it

[alphabravo321] 20/1/2021 12:36

Thats a big trade!